Mölndal, Sweden

Erik Söderlind



Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 118(Granted Patents)


Company Filing History:


Years Active: 2005-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Erik Söderlind: Innovator in Pharmaceutical Science

Introduction

Erik Söderlind is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical science, particularly in the development of innovative delivery systems and surfactants. With a total of 2 patents, his work has the potential to impact various medical applications.

Latest Patents

Söderlind's latest patents include "Non-ionic surfactants for poorly soluble molecules" and "Antigen delivery system and method of production." The first patent focuses on new non-ionic surfactants that enhance the solubility of poorly soluble molecules. These surfactants are derived from polyoxyalkylene glycol hydroxy fatty acid derivatives and are prepared through an enzymatic process. The second patent addresses a polymer particle vaccine delivery system that incorporates water-insoluble protein antigens, such as lipidated HpaA protein, into a polymer matrix. This innovative system aims to improve vaccine efficacy and reduce the risk of infections, such as Helicobacter.

Career Highlights

Erik Söderlind is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on developing advanced pharmaceutical solutions that address critical health challenges.

Collaborations

Söderlind has collaborated with notable colleagues, including Hans Carlsson and Anette Larsson. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical sector.

Conclusion

Erik Söderlind's contributions to pharmaceutical science through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in drug delivery systems and vaccine development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…